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Abstract
Background: Long term treatment with immunosuppressive agents results in nephrotoxicity in
renal transplant recipients. We explored the effect of combination of Tacrolimus (TAC) and
Sirolimus (SRL) on the immune system in renal transplant recipients.
Methods: 10 stable renal transplant recipients were selected to participate in a pharmacokinetic
study with a combination of TAC and SRL. Blood was drawn on day zero and 14 days post
treatment. Lymphocyte proliferation was quantified by 3H-thymidine uptake assay (results
expressed as counts per minute). The mRNA expression was studied by RT-PCR and serum levels
of cytokines were quantified by ELISA and a cytokine bead array system.
Results: Lymphocyte proliferative response to PHA (p < 0.05), Con A (p < 0.006) and Anti-CD3
(p <0.005) were significantly decreased in patients who received both TAC and SRL compared to
TAC alone. The mRNA expression of proinflammatory cytokines TNF-α (p < 0.05), cyclins G (p <
0.01) and E (p < 05) were decreased, and of TGF-β (p < 0.03) and p21 (p < 0.05) were increased
in patients treated with this combination. Circulating levels of IFN-γ (p < 0.04), IL-4 (p < 0.02), and
Il-2 (p < 0.03) were significantly inhibited and elevation of TGF-β (p < 0.04) was observed in patients
treated with TAC and SRL combination.
Conclusion: These novel findings demonstrate that addition of SRL to TAC therapy enhances
immuno modulation and causes increased immunosuppression providing a rationale for this
concomitant therapy.
Background
Cyclosporine (CsA) and tacrolimus (TAC) are the primary
immunosuppressive drugs used for the prevention of
acute rejection after renal transplantation. The long-term
treatment of patients with either CsA or TAC results in side
effects such as nephrotoxicity, hypertension, and gingival
hyperplasia [1,2]. Sirolimus (SRL) a new immunosup-
pressive agent is structurally similar to TAC binds to same
binding protein FKBP, but its mechanism of action is dif-
ferent [3]. Both clinical and experimental studies demon-
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strated that SRL when used either with CsA or alone is
associated with side effects such as hyperlipidemia,
thrombocytopenia and nephrotoxicity [4–7]. Since SRL
and TAC have affinity for the same binding site, it was
thought to be ineffective when used together. However,
experimental and clinical studies have refuted this as-
sumption, and have successfully demonstrated the effica-
cy of this combination therapy [8–10].
Encouraged by our recent in vitro study [11] that demon-
strated a significant inhibition of lymphocyte prolifera-
tion, IL-2 and induction of TGF-β expression by
combination of sub-clinical concentration of SRL with ei-
ther TAC or CsA, we conducted the current study on renal
transplant recipients. A total of 10 stable renal transplant
recipients were selected to participate in a pharmacokinet-
ic (PK) and immune function study with combination of
TAC and SRL therapy in human transplant. The current
study describes the analysis of immune function in stable
renal transplant recipients with SRL and TAC combina-
tion therapy.
Methods
Study subjects/Patients
Stable renal transplant recipients receiving TAC based im-
munosuppression were included in this study. Definition
of "stable" transplant patients is based on post transplant
care, renal function, acute rejection episodes. A total of 10
patients were enrolled after informed consent. Azathio-
prine/MMF (Mycophenolate Motefil) were discontinued
prior to initiation of SRL and all patients were on corticos-
teroids. On day zero (24 h) after discontinuation of Aza/
MMF), blood samples were collected at time zero (base-
line) and 12 h after the administration of TAC for lym-
phocyte proliferation and cytokine expression at the gene
and protein level. SRL was started on day 0 and patients
were maintained on the same dose of TAC and SRL for 14
days. Blood samples were repeated on day 14 for immune
functions, again at time zero (baseline and 12 h after). The
graphic representation of the treatment protocol is shown
in figure 1. The effect of this concomitant therapy on the
immune function was studied by quantifying lymphocyte
proliferation and the mRNA expression of TGF-β, TNF-α,
IL-10, IL-6, IFN-γ by RT-PCR assay. Serum levels of cy-
tokines (IFN-γ, TNF-α, IL-10, and IL-2) were quantified by
a cytokine bead array system and TGF-β specific ELISA.
Trough levels of TAC and SRL were not available as they
were processed in central core laboratory as a part of mul-
ticenter study.
Preparation of lymphocytes and Experimental Protocol
Peripheral blood mononuclear cells from the blood of re-
nal transplants obtained at time zero (day # 0) and (day #
14) were separated by ficoll-hypaque as described by ear-
lier [11]. Briefly, lymphocytes were washed twice in Phos-
phate Buffered Saline (PBS) and suspended in RPMI
containing 5% FBS and Penicillin-Streptomycin. Lym-
phocytes were counted and adjusted to 1 × 106/ml and
200,000 cells were plated in a 96-well plate. Cells were
cultured at 37 C in an ambient environment with 5% CO2
air with PHA (2 µg/ml), ConA (2 µg/ml) and anti-CD3
(100 ng/ml) for 60–70 h and last 16 hours with 3H-thy-
midine (1 µCi/well). The cells were then harvested on fil-
ter papers using a harvester, filter papers were dried and
were then transferred to liquid scintillation vials and [3H]
thymidine uptake were quantified as counts per minute
(CPM) using a liquid scintillation counter.
Detection of mRNA by reverse transcription and polymer-
ase chain reaction (RT-PCR)
Total RNA was isolated from lymphocytes isolated from
blood obtained from patients using Trizol isolation Sys-
tem (Life Sciences, Invitrogen) and quality of RNA was
verified by 260/280-nm ratio. 1 µg of RNA was reverse
transcribed to cDNA using Superscript First Strand Syn-
thesis system for RT-PCR (Life Technologies Rockville
MD, USA). The amplification by polymerase chain reac-
tion (PCR) was carried out using 1 µl of cDNA, and 2 µl
each of 2.5 mM coding and non-coding oligonucleotide
primers and Platinum PCR Supermix (Life Technologies
Rockville MD, USA). The primer sequences of TGF-β, β-ac-
tin and p21 are described in our earlier studies [11,12].
The primer sequences for other genes are: TNF-α; coding
5'-AAGAATTCAAACTGGGGCCT-3' and noncoding: 5'-
GGCTACATGG GAACAG CCTA-3' [13] Cyclin G: coding
5'-TGAAGCCTCAAAACATCACG-3' and noncoding 5'-
CAGTGAT TGAAGCTGTG GGA-3' [14]; Cyclin E: coding
5'-TATACTTGCTGCTTC GGCCT-3' and non coding 5'-
CTGCTCTGCTTC TTACCGCT-3' [15]; IL-6: coding 5' AT-
Figure 1
Treatment protocol: A time line of treatment with TAC
with MMF/AZA and steroids and TAC and SRL. Vertical
arrows show times when blood samples were drawn.
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GAACTCCTTCTC CACAAGCGC-3' and non coding 5'-
GAAGAGCCCTCA GGCTGGACTGC-3' [16]; IL-10: cod-
ing 5'-AAGCCTGACCACGCTTTCTA-3'; and non coding
5'-CTCAGCCT CCCAAGT AGCTG-3' [17]; IFN-γ: coding
5'-GCGAAAAAG GAGTCAGA TGC-3'; and non coding 5'-
TGGGATCTTGCTTAGGTTGG-3' [18]; The PCR products
were resolved in 1% agarose gel electrophoresis, ethidium
bromide stained specific bands will be visualised under
UV light and photographed. The densitometric analysis of
the specific bands was made using Alpha-Imager (Alpha
Innotech Corp. San Leandro CA USA) and data are repre-
sented as the ratio of the specific gene to β-actin.
Cytokine Bead Array
We studied the expression of circulating levels of cy-
tokines IFN-γ, TNF-α, IL-10, IL-5, IL-4 and IL-2 in sera of
patients using a new cytokine bead array system (BD Bio-
sciences San Diego CA, USA). This method also named
multiplexed bead assay is comprised of spectrally discrete
particles, which can be used to quantitative soluble parti-
cles, in this case cytokines using a fluorescence based de-
tection mechanism and flowcytometric analysis. The
beads coated with IFN-γ, TNF-α, IL-10, IL-5, IL-4 and IL-2
react with test sera and standards, to which fluorescence
dyes are then added. The flowcytometric analysis using
special software allows the calculation of concentrations
in the unknown sera.
Quantification TGF-β protein in sera
Circulating levels of TGF-β1 protein in patients' sera were
quantified using the TGF-β specific ELISA (Promega, Mad-
ison, and USA), as described by us earlier [11].
Data Analysis
Statistical analyses were performed by using statistical
program purchased from GraphPad Software, Inc.(San
Diego, CA USA). The results are expressed as Mean ± SEM
and a two-tailed p value of < 0.05 was considered signifi-
cant.
Results
Clinical Parameters
The mean age of patients included in this study was 45
years (32–56 years). The study was conducted after a
mean period of 49 months (16–70 months) post-trans-
plantation. The mean plasma creatinine prior to SRL ther-
apy was 1.3 mg/dl (1.0–1.7 mg/dl) and was 1.2 mg/dl
(0.9–1.6 mg/dl) at the end of 14 days. The mean TAC dose
and level prior to SRL therapy was 6.5 mg/day (4–10) and
8 ng (6–14 ng/ml). The TAC dose was not adjusted during
the study period and mean TAC level at 14 days was 6 ng/
ml (4–13 ng/ml). None of these recipients experienced
acute rejection or any other side effects with this therapy.
The exact SRL levels were not available as they were proc-
essed in central core laboratories, however were main-
tained at therapeutic level.
Figure 2
Effect of different treatment protocols on lym-
phocyte proliferation: Peripheral blood mononuclear cells
from the blood of renal transplants obtained on (day # 0) and
on (day # 14) were separated by ficoll-hypaque. [3H]-thymi-
dine uptake was quantified as counts per minute (CPM) using
a liquid scintillation counter. The open bars represent the
proliferation data (Mean ± SEM) of lymphocyte proliferation
from patients treated with TAC/MMF/AZA and steroids and
closed bars represent data after addition of SRL to TAC (day
# 14) without MMF/AZA.
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TGF-β and p21 mRNA expression: TGF-β and p21
mRNA with housekeeping gene β-actin with TAC/MMF/Aza
(day #0) and TAC and SRL (day# 14) are shown in the figure.
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Effect of concomitant tacrolimus and rapamycin therapy 
on lymphocyte proliferation
The proliferation of lymphocytes from patients treated
with TAC and SRL were compared with lymphocytes from
patients treated with TAC and MMF/Aza. The results are
shown in Figure 2 which, demonstrated a significant inhi-
bition of proliferation of lymphocytes from patients with
TAC and SRL compared to TAC plus MMF/Aza. (PHA:
17510 ± 4094 vs 10963 ± 3008 p < 0.05; ConA: 23995 ±
2449 vs 12124 ± 2946 p < 0.006; and anti-CD3: 27089 ±
1557 vs 16093 ± 3097 p < 0.005).
Effect of concomitant tacrolimus and rapamycin therapy 
on gene expression in lymphocytes
We compared the mRNA expression of cytokines; IFN-γ,
TNF-α, Il-6, IL-10 and growth regulatory molecules; TGF-
β, p21 and cyclins E and G in lymphocytes from patients
treated with TAC + MMF/Aza and TAC + SRL.
i) TGF-β mRNA
As shown in figure 3, expression of TGF-β in lymphocytes
from patients treated with both TAC and SRL expressed as
ratio with β-actin (0.9 ± 0.12) significantly increased (p <
0.03), when compared to TAC and MMF/Aza (0.5 ± 0.12).
ii) p21 mRNA expression
The results are expressed as ratio of p21 with β-actin dem-
onstrate a significant (p < 0.05) increase in patients treat-
ed with both TAC and SRL (1.02 ± 0.25), when compared
with patients when they were treated with TAC and MMF/
Aza (0.5 ± 0.24) {Figure 3}.
iii) IL-6 and IL-10 mRNA
Figure 4 illustrates comparison of the IL-6 and IL-10
mRNA expression in patients treated with TAC/MMF/Aza
and TAC/SRL. The results are expressed as ratio with β-ac-
tin, a significant (p < 0.01) increase in IL-10 mRNA in pa-
tients treated with both TAC and SRL (0.84 ± 0.1), when
compared with TAC and MMF/Aza (0.47 ± 0.1). Though
an increase in IL-6 mRNA was observed in renal transplant
recipients treated with TAC/SRL (0.72 ± 0.2) compared to
patients treated with TAC/MMF/Aza (0.59 ± 0.16), the dif-
ference was not significant.
iv) TNF-α mRNA
We also studied the effect of SRL on pro-inflammatory cy-
tokine TNF-α in lymphocytes from these patients (Figure
4). The results expressed as ratio with β-actin, demon-
strate a marked decrease (p < 0.05) in TNF-α levels in lym-
phocytes from patients treated with TAC and SRL (0.22 ±
0.08) compared to patients treated with TAC/MMF/Aza
(0.11 ± 0.05).
v) Cyclin mRNA expression
The results of cyclins G and E mRNA expressed as ratio
with β-actin shown in Figure 5. A significant decrease (p <
0.01) in Cyclin G mRNA in lymphocytes from patients
treated with TAC and SRL (0.23 ± 0.05) compared to pa-
tients treated with TAC/MMF/Aza (0.08 ± 0.01). Similarly,
a significant decrease (p < 0.01) in Cyclin E mRNA was
noted with TAC and SRL (0.2 ± 0.04) compared to TAC/
MMF/Aza (0.1 ± 0.01). Combination of decreased expres-
sion of cyclin and increased p21 mRNA expression corre-
lates with the decreased lymphocyte proliferation.
Figure 4
IL-6, IL-10 and TNF-α mRNA expression: The ratios of
IL-6, IL-10 and TNF-α with housekeeping gene β-actin with
TAC/MMF/Aza (day #0) and TAC and SRL (day # 14) are
shown in the figure.
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Figure 5
Cyclins G and E mRNA expression: The ratios of Cyc-
lins G and E with housekeeping gene β-actin with TAC/MMF/
Aza (day #0) and TAC and SRL (day #14) are shown in the
figure.
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Circulating levels of cytokines
Combination of TAC and SRL resulted in a significant in-
hibition of cytokines in sera of patients compared to pa-
tients treated with TAC/MMF/Aza. The results shown in
Figure 6 are expressed as pg/ml; IFN-γ(9 ± 2 vs 6 ± 1.6, p <
0.04), IL-4 (7 ± 0.35 vs 5.8 ± 0.36, p < 0.02) and IL-2 (7 ±
0.36 vs 6 ± 0.26 p < 0.03) without any change in the levels
of TNF-α, IL-5 and IL-10.
TGF-β protein expression in sera of patients
Since we observed a significant increase in TGF-β mRNA
expression in lymphocytes from patients treated with
combination of TAC and SRL compared to TAC/MMF/
Aza, we also studied circulating levels of total TGF-β pro-
tein in acid activated sera from these patients. The results
(figure 7) demonstrate statistically increased levels (p <
0.04) of TGF-β in renal transplant recipients after addition
of SRL to TAC (107 ± 17.7 ng/ml vs 135 ± 18 ng/ml).
These results demonstrate that decreased lymphocyte pro-
liferation in part may be due to increased levels of TGF-β
in these patients.
Discussion
A number of studies have demonstrated that long treat-
ment of both CsA and TAC is associated many side effects
such as nephrotoxicity, hypertension, and gingival hyper-
plasia [1,2]. Rapamycin clinically termed, as Sirolimus
(SRL) is a new immunosuppressive agent, which is struc-
turally similar to TAC, binds to same binding protein
FKBP, but has different mechanism of action [3]. Both
clinical and experimental studies demonstrated that SRL
when used either with CsA or alone is associated with side
effects like hyperlipidemia, thrombocytopenia and neph-
rotoxicity [4–7]. SRL and TAC compete for the same bind-
ing site and hence it was thought they could not be used
concomitantly. However, recent experimental and clinical
studies have refuted this assumption, and have successful-
ly used this combination therapy [8–10]. Therefore there
is need of an alternate strategy to use these drugs to treat
renal transplant recipients. Recently [11], we have demon-
strated the efficacy of combination of low doses of SRL
with either CsA or TAC to inhibit lymphocyte prolifera-
tion. The results from this study also demonstrate the in-
creased immuno modulation in renal transplant
recipients by this therapy. The synergistic effect of SRL and
CsA has been demonstrated in animal models and clinical
transplantation [19,20]. This prompted us to explore the
mechanistic action of SRL and TAC when used in combi-
nation. Patients when received a concomitant therapy of
TAC and SRL exhibited a significant inhibition of their
lymphocytes when cultured with mitogens; PHA, ConA
and anti-CD3, compared to the proliferation of lym-
phocytes obtained from when they were treated with TAC
and MMF/Aza. Such a sustained effect is expected to pre-
vent graft rejection, demonstrating the efficacy of this
combination in renal transplant recipients.
To analyse the mechanism of the effect of concomitant
therapy of TAC and SRL on lymphocyte proliferation, we
studied the mRNA expression of TGF-β, p21, IFN-γ, TNF-
α, Il-6, IL-10, cyclins G and E. The results demonstrated a
significant increase in TGF-β mRNA expression (p < 0.03)
with TAC and SRL. The expression of p21 mRNA was also
increased in renal transplant recipients with this therapy.
These results are consistent with our previous studies
[21,22], that TGF-β mediates in part the immunosuppres-
sive effects of CsA and TAC. Current study supports our
hypothesis that the immunosuppression results in an in-
creased expression of cyclin inhibitor p21, which by in-
hibiting the expression of cyclins controls the allo-
immune activation. Since p21 is one of the most potent
cyclin inhibitor, these results may explain the significant
inhibition of proliferation of lymphocytes may in part be
due to the increased p21 expression. The expression of cy-
clin E and G, which controls the cell cycle progression and
G0/S and G1 phase of cell cycle, was decreased with TAC
and SRL therapy. The expression of cyclins also corre-
sponds to the decreased lymphocyte proliferation with
SRL and TAC therapy.
We noted an increased expression of IL-6 and IL-10
mRNA in lymphocytes from patients with concomitant
therapy with TAC and SRL. A number of experimental and
clinical studies [23,24] have demonstrated IL-10 expres-
sion to be beneficial and correlates with increased graft
survival. The results from this study demonstrate down
regulation of cyclins, and up-regulation of cyclin inhibitor
p21 and IL-10 mRNA expression.
Figure 6
Circulating levels of proinflammatory cytokines: Sig-
nificantly decreased levels of IFN-γ (p < 0.04), IL-4 (p < 0.02)
and IL-2 (p < 0.03) in patients treated with TAC and SRL
compared to TAC/MMF/Aza are shown.
0
2
4
6
8
10
12
14
IFN-gamma IL-4 Il-2
p
g
/
m
l
Tacrolimus/MMF/Aza
Tacrolimus+Sirolimus p<0.04
p<0.02 p<0.03Medical Immunology 2002, 1 http://www.medimmunol.com/content/1/1/3
Page 6 of 7
(page number not for citation purposes)
IL-6, like IL-10 has also been considered to possess both
pro- and anti-inflammatory properties [25,26]. In this
study, we observed an increase in mRNA expression of IL-
6. Acute rejection has been associated with increased in-
tragraft IL-6 protein and mRNA production [27]. Howev-
er, other studies have failed to demonstrate any
correlation between IL-6 production and rejection [28].
The current study demonstrate that a concomitant therapy
of TAC and SRL increases expression of IL-6 mRNA in
lymphocytes and its significant remains to be evaluated.
We also quantified circulating levels of TGF-β, IL-2, IL-4,
TNF-α, and IFN-γ. The results from this study demonstrate
that addition of SRL to TAC therapy results in a significant
(p < 0.04) increase in circulating levels of TGF-β. We have
earlier demonstrated that TGF-β in part mediates the im-
munosuppressive effects of these drugs [11,12,21,22] and
therefore the increased levels of TGF-β may partially ex-
plain the increased inhibition of mitogen induced lym-
phocyte proliferation. Though the role of TGF-β has been
correlated with drug induced nephrotoxicity [29] it is ear-
ly to speculate if this combination will also result in an in-
creased nephrotoxic effects. We are unable to demonstrate
the nephrotoxicity with this combination due to short
course of therapy.
The levels of IFN-γ, IL-4 and IL-2 were decreased substan-
tially with SRL and TAC therapy {IFN-γ (p < 0.04), IL-4 (p
< 0.02) and IL-2 (p < 0.03)}. This indicates that the inhi-
bition of lymphocyte proliferation with SRL also resulted
in decreased inflammatory response.
Conclusions
In conclusion, these results provide evidence to potential
efficacy of TAC and SRL combination therapy in renal
transplant recipients. The addition of SRL to the immuno-
suppressive regimen of Tac resulted in decreased lym-
phocyte proliferation exhibiting decreased allo-immune
response. Also, mRNA expression of proinflammatory cy-
tokines TNF-α, Interferon-γ and cyclins G1, and E were
significantly decreased and the expression of TGF-β and
p21 were increased. The addition of SRL significantly de-
creased the circulating levels of pro-inflammatory cy-
tokines and conversely increased the circulating levels of
TGF-β, partially explaining the increased immunosup-
pression in these patients. However, due to short span of
this treatment, the nephrotoxic effects remains unclear.
These novel findings provide a mechanism and rationale
for a concomitant therapy with TAC and SRL in renal
transplant patients.
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